期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌患者血浆凝血酶激活的纤溶抑制物和组织因子途径抑制物及凝血酶原片段1＋2的水平变化及临床意义 被引量：6

原文传递
导出
摘要 肿瘤导致的止凝血异常发生率较高，其病理生理变化主要为高凝状态或易栓症，临床表现为血栓形成和弥散性血管内凝血（ disseminated intravascular coagulation, DIC ）。
作者 刘延鹏 李玲 纪全江 王胜江 徐成伟
机构地区 山东大学第二医院医疗保险科 山东省医学科学院附属医院胸外科 山东省医学科学院附属医院检验科 山东大学第二医院检验科
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2012年第5期466-468,共3页 Chinese Journal of Laboratory Medicine
基金 山东省自然科学基金资助项目（ZR2009CM083）
关键词 凝血酶激活的纤溶抑制物 凝血酶原片段1+2 组织因子途径抑制物 INTRAVASCULAR 临床意义 水平变化 肺癌患者 非小细胞
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献9

  • 1徐成伟,王丽丽,吴晓本,赵敬杰,杜贻萌,姜翠英.冠状动脉粥样硬化性心脏病患者凝血酶激活的纤溶抑制物及其编码区基因多态性的研究[J].中华医学遗传学杂志,2008,25(4):438-442. 被引量：3
  • 2徐成伟,吴晓本,许顺良,宁尚义,王泽筠.凝血酶激活的纤溶抑制物编码区基因多态性与脑梗塞亚型的关系[J].中华检验医学杂志,2009,32(6):685-688. 被引量：2
  • 3李晓娜,丁进芳,王凤兰,钟兰君,李芳文,边玉军,张兴旺.凝血酶激活的纤溶抑制物与2型糖尿病微量白蛋白尿症的关系[J].中华检验医学杂志,2006,29(7):620-621. 被引量：2
  • 4Hataji O, Taguchi O, Gabazza EC, et al. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol,2004, 76:214-219.
  • 5Koldas M, Gummus M, Seker M, et al. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer. Clin Lung Cancer,2008, 9 : 112-115.
  • 6Donati MB. Thrombosis and cancer: Trousseau syndrome revisited. Best Pract Res Clin Haematol,2009 ,22 :3-8.
  • 7Zacharski LR, Ornstein DL. Venous thromboembolism and cancer. N Engl J Med,2000,343 : 1338.
  • 8Pavey S J, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with nonsmall cell lung carcinoma. Blood Coagul Fibfinolysis ,2001,12:51-58.
  • 9Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-aetivatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem, 2007, 40: 431-442.

二级参考文献28

  • 1董宁征,吴成亮,季顺东,江淼,阮长耿.PAI-1和TAFIa对机体内源性纤溶的调控作用[J].江苏医药,2004,30(10):749-750. 被引量：5
  • 2各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379-380. 被引量：33093
  • 3Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem, 1995, 270:14477-14484.
  • 4VanhoofG, Wauters J, Schatteman K, et al. The gene for human carboxypeptidase U(cpu)-A proposed novel regulator of plasminogen activation-maps to 13q14.11. Genomics, 1996,38:454-455.
  • 5Brouwers GJ, Vos HL, Leebeek FW, etal. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-aetivatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood, 2001,98 : 1992-1993.
  • 6Michael BB, Marlys LK. Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles (review). Clin Biochem, 2007,40:431-442.
  • 7Bjorkman JA, Abrahamsson TI, Nerme VK, etal. Inhibition of carboxypeptidase U (TAFIa) activityimproves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis. Thromb Res ,2005,116:519-524.
  • 8Schroeder V, Chatterjee T, Mehta H, et al. Thrombin activatable fibrinolysisinhibitor (TAFI) levels in patients with coronary artery disease investigated byangiography. Thromb Haemost, 2002,88 : 1020-1025.
  • 9Segev A, Hegele RA, Lau HK, et al. Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographie restenosis after percutaneous coronary interventions. Thromb Res, 2004, 114 : 137- 141.
  • 10Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood, 2001,97 : 2053-2058.

共引文献3

同被引文献61

  • 1王明山,杨丽红,潘景业,王霄霞,陆红,吕美艳,陈少贤,谢于鹏.晚期肺癌患者化疗过程中抗凝血酶和纤溶功能的变化及意义[J].中国肺癌杂志,2007,10(3):226-228. 被引量：13
  • 2Komurcuoglu B, Ulusoy S, Gayaf M, et al. Prognostic value of plasma D-dimer levels in lung carcinoma[J].Tumori, 2011, 97(6): 743.
  • 3Zhao j, Zhao M, Jin B, et al. Tumor response and survival in patients with advanced non-small-cell lung cancer: the pre- dictive value of chemotherapy-induced changes in fibrinogen [J]. BMC Cancer, 2012, 12(1 ) : 330.
  • 4Thaler J, Ay C, Pabinger I. Clinical significance of circulat- ing microparticles for venous thromboembolism in cancer pa- tients[J]. Hamostaseologie, 2012, 32(2): 127.
  • 5Pangilinan J M. Venous thromboembolism in patients with cancer: an overview for pharmacists using a case-based ap- proach[J]. J Pharm Pract, 2010, 23(4):294.
  • 6Battinelli E M, Murphy D L, Connors J M. Venous throm- boembolism overview [J]. Hematol Oncol Clin North Am, 2012, 26(2): 345.
  • 7Kuderer N M, Ortel T L, Francis C W. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival[J]. J Clin Oncol, 2009, 27(29): 4902.
  • 8Sasao H, Fujiwara H, Murai H, et al. Does motor dysfunction after cerebral infarction impede the development of angina symptoms. A comparison of coronary angiographic findings in patients with and without prior cerebral infarction [J] .Int Heart J,2013,54(1) :1-6.
  • 9Zhang XM, Wang WJ, Yu YL, et al.BNP and NT-proBNP assays for heart-failure diagnosis in patients with cerebral in- farction[ J] .Laboratory Medicine, 2013,44( 1 ) :46-50.
  • 10Ejaz S, Williamson DJ, Ahmed T, et al. Characterizing in- farction and selective neuronal loss following temporary focal cerebral ischemia in the rat: a multi-modality imaging study [ J]. Neurobiol Dis ,2013,51 : 120-132.

引证文献6

二级引证文献41

中华检验医学杂志
2012年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部